# VCEL catalysts: Vericel Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vcel/catalysts

> Vericel Corp (VCEL) has 4 upcoming catalysts. The next is the maci primary completion, February 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Vericel Corp |
| Ticker | VCEL (Nasdaq) |
| SEC CIK | 887359 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/vcel |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 15, 2024 | [NexoBrid (anacaulase) FDA approval](https://sec-api.dev/pdufa/anacaulase) | VCEL | deep partial-thickness and/or full-thickness thermal burns | completed, approved | "On August 15, 2024, we announced the FDA approval of a pediatric indication for NexoBrid for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm)) |
| January 14, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000114036125001060/ef20041599_ex99-1.htm)) |
| February 27, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025008444/ex991earningsreleaseq42024.htm)) |
| May 8, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/ex991earningsreleaseq12025.htm)) |
| July 31, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/ex991earningsreleaseq22025.htm)) |
| November 6, 2025 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828025049880/ex991earningsreleaseq32025.htm)) |
| January 13, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Announces Preliminary 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_ex99-1.htm)) |
| February 26, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026012003/ex991earningsreleaseq42025.htm)) |
| May 7, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026031713/ex991earningsreleaseq12026.htm)) |
| July 30, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/ex991earningsreleaseq22026.htm)) |
| November 5, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026070622/ex991earningsreleaseq32026.htm)) |
| February 2030 | [Maci primary completion](https://sec-api.dev/pdufa/maci) | VCEL | Chondral Defect; Osteochondritis Dissecans (OCD); Articular Cartilage Defect | scheduled | "NCT03588975 (A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor Vericel Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03588975)) |
| Feb to May 2030 | [Maci topline data readout](https://sec-api.dev/pdufa/maci) | VCEL | Chondral Defect; Osteochondritis Dissecans (OCD); Articular Cartilage Defect | scheduled | "NCT03588975 (A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor Vericel Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03588975)) |
| July 2030 | [Autologous cultured chondrocytes on porcine collagen membrane primary completion](https://sec-api.dev/pdufa/autologous-cultured-chondrocytes-on-porcine-collagen-membrane) | VCEL | Chondral Defect; Articular Cartilage Defect | scheduled | "NCT06915233 (A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Vericel Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06915233)) |
| Jul to Oct 2030 | [Autologous cultured chondrocytes on porcine collagen membrane topline data readout](https://sec-api.dev/pdufa/autologous-cultured-chondrocytes-on-porcine-collagen-membrane) | VCEL | Chondral Defect; Articular Cartilage Defect | scheduled | "NCT06915233 (A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Vericel Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06915233)) |

## Drugs

- [Autologous cultured chondrocytes on porcine collagen membrane](https://sec-api.dev/pdufa/autologous-cultured-chondrocytes-on-porcine-collagen-membrane): Chondral Defect
- [Maci](https://sec-api.dev/pdufa/maci): Chondral Defect

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vcel/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VCEL catalysts: Vericel Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vcel/catalysts

```bibtex
@misc{secapidev_companies_vcel_catalysts_20261116,
  title        = {VCEL catalysts: Vericel Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vcel/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vcel_catalysts_20261116","title":"VCEL catalysts: Vericel Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vcel/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
